<DOC>
	<DOCNO>NCT02165189</DOCNO>
	<brief_summary>The purpose study evaluate sustain virologic response 12 week end treatment ( SVR12 ) follow 12 week simeprevir plus sofosbuvir without ribavirin ( RBV ) 24 week simeprevir plus sofosbuvir without RBV post orthotopic liver transplant participant recurrent hepatitis ( inflammation liver ) C virus ( HCV ) Genotype 1 infection .</brief_summary>
	<brief_title>An Efficacy Safety Study Simeprevir Sofosbuvir With Without Ribavirin Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant</brief_title>
	<detailed_description>This Phase 2 , multicenter ( one hospital medical school team work medical research study ) , partially randomize ( study drug assign chance ) , open-label ( people know identity intervention ) study explore safety efficacy simeprevir plus sofosbuvir . The study consist screen period ( Screening Baseline ) , follow randomization . First 33 non-cirrhotic participant randomly assign ratio 1:1:1 1 3 treatment arm , 12 cirrhotic participant enrol assigned Arm 3 . All participant treatment Arms 1 2 return treatment visit Weeks 1 , 2 , 4 , 8 , 12 , post-treatment follow-up visit Weeks 16 24 . All participant treatment Arm 3 return treatment visit Weeks 1 , 2 , 4 , 8 , 12 , 16 , 20 , 24 , post-treatment follow-up visit Weeks 28 36 . Participants receive simeprevir plus sofosbuvir RBV 12-week treatment period Arm 1 , simeprevir plus sofosbuvir without RBV 12-week treatment period Arm 2 simeprevir plus sofosbuvir 24-week treatment period Arm 3 . Efficacy primarily evaluate SVR12 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Participant must infect Hepatitis C virus ( HCV ) Genotype 1 ( 1a 1b ) Baseline HCV ribonucleic acid ( RNA ) great ( &gt; ) 10,000 international unit per milliliter ( IU/mL ) . Retesting HCV RNA ass eligibility allow , use unscheduled visit Screening period Participant must orthotopic liver transplant great equal ( &gt; = ) 6 month 15 year prior enrollment Participant must primary liver transplant Participant must stable immunosuppressive regimen least 3 month prior Screening visit . Immunosuppression regimens may include calcineurin inhibitor ( example , tacrolimus ) , mammalian target rapamycin ( mTOR ) inhibitor , mycophenolate mofetil , prednisone , prednisolone less equal ( &lt; = ) 5 milligram per day ( mg/day ) , corticosteroid ( except systemic dexamethasone ) , sirolimus , everolimus , azathioprine . Stable immunosuppression include normal adjustment immunosuppressant dose excludes change immunosuppressant medication and/or treatment rejection . Participant 's renal function measure Cockcroft Gault formula must &gt; 30 milliliter per minute ( mL/min ) Participants received prior treatment investigational Food Drug Administration ( FDA ) approve directacting antiviral drug treatment hepatitis C. Prior HCV treatment interferon peginterferon without ribavirin ( RBV ) allow must complete least 3 month prior Screening Participants hepatic decompensation define follow : 1 ) Any postliver transplant clinical sign include ascites , hepatic encephalopathy , and/or evidence varix without variceal bleeding , 2 ) ChildTurcottePugh ( CTP ) score &gt; =7 Participant ( posttransplant ) underlie serious lifethreatening condition , severe uncontrolled cardiopulmonary disease , vascular disease , rheumatologic condition , renal failure , dialysis , ongoing systemic infection , uncontrolled malignancy , serious illness would compromise adherence medication ability comply aspect study protocol Any active , clinically significant disease clinically significant finding Screening period medical history , physical examination , laboratory testing , electrocardiogram ( ECG ) recording , investigator 's opinion , would compromise participant 's safety could interfere participant participate complete study . Retesting laboratory result lead exclusion allow use unscheduled visit Screening period ass eligibility Participant woman pregnant , breastfeeding , plan become pregnant enrolled study within 6 month last dose ribavirin ( longer dictate local regulation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Simeprevir</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Hepatitits C</keyword>
	<keyword>Hepatitis C virus ribonucleic acid</keyword>
</DOC>